Laser Photonics Advances Pill Drilling R&D to Increase Presence in Pharmaceutical Market
Laser Photonics (NASDAQ: LASE), along with its recently acquired subsidiary Control Micro Systems (CMS), announced the expansion of its tablet laser drilling technology development program for the pharmaceutical market. The technology creates sub-millimeter holes in pharmaceutical tablets for osmotic pump time-release drug delivery systems, processing up to 140,000 tablets per hour with orifices as small as 200 microns.
The system features machine vision technology for quality control, checking each tablet twice for hole position, size, and quantity. This expansion represents LPC's strategic move into the pharmaceutical sector, leveraging CMS expertise to diversify its portfolio beyond industrial laser cleaning applications.
Laser Photonics (NASDAQ: LASE), insieme alla sua recente acquisizione Control Micro Systems (CMS), ha annunciato l'espansione del programma di sviluppo della tecnologia di perforazione laser per compresse destinate al mercato farmaceutico. Questa tecnologia crea fori sub-millimetrici nelle compresse farmaceutiche per i sistemi di rilascio controllato di farmaci a pompa osmotica, elaborando fino a 140.000 compresse all'ora con orifizi piccoli fino a 200 micron.
Il sistema è dotato di tecnologia di visione artificiale per il controllo qualità, verificando ogni compressa due volte per posizione, dimensione e quantità del foro. Questa espansione rappresenta una mossa strategica di LPC nel settore farmaceutico, sfruttando l'expertise di CMS per diversificare il proprio portafoglio oltre alle applicazioni di pulizia laser industriale.
Laser Photonics (NASDAQ: LASE), junto con su subsidiaria recientemente adquirida Control Micro Systems (CMS), anunció la expansión de su programa de desarrollo de tecnología de perforación láser para tabletas en el mercado farmacéutico. Esta tecnología crea agujeros submilimétricos en las tabletas farmacéuticas para sistemas de liberación controlada de medicamentos mediante bomba osmótica, procesando hasta 140,000 tabletas por hora con orificios tan pequeños como 200 micrones.
El sistema incluye tecnología de visión artificial para el control de calidad, revisando cada tableta dos veces para verificar la posición, tamaño y cantidad de los agujeros. Esta expansión representa un movimiento estratégico de LPC hacia el sector farmacéutico, aprovechando la experiencia de CMS para diversificar su cartera más allá de las aplicaciones de limpieza láser industrial.
레이저 포토닉스 (NASDAQ: LASE)는 최근 인수한 자회사의 Control Micro Systems (CMS)와 함께 제약 시장을 위한 태블릿 레이저 드릴링 기술 개발 프로그램의 확장을 발표했습니다. 이 기술은 삼투 펌프 시간 방출 약물 전달 시스템을 위해 제약 태블릿에 0.5mm 크기의 구멍을 생성하며, 시간당 최대 140,000 개의 태블릿을 처리할 수 있습니다; 구멍 크기는 200 마이크론까지 작습니다.
시스템은 품질 관리를 위한 머신 비전 기술을 갖추고 있으며, 각 태블릿의 구멍 위치, 크기 및 수량을 두 번 확인합니다. 이번 확장은 LPC가 제약 분야로 진출하는 전략적 이동을 의미하며, CMS의 전문성을 활용하여 산업용 레이저 청소 애플리케이션 이상의 포트폴리오를 다각화할 계획입니다.
Laser Photonics (NASDAQ: LASE), ainsi que sa récente filiale acquise Control Micro Systems (CMS), a annoncé l'expansion de son programme de développement de la technologie de perçage laser pour les comprimés sur le marché pharmaceutique. Cette technologie crée des trous sub-millimétriques dans les comprimés pharmaceutiques pour les systèmes de libération contrôlée de médicaments par pompe osmotique, traitant jusqu'à 140 000 comprimés par heure avec des orifices aussi petits que 200 microns.
Le système est doté d'une technologie de vision machine pour le contrôle qualité, vérifiant chaque comprimé deux fois pour la position, la taille et la quantité des trous. Cette expansion représente un mouvement stratégique de LPC vers le secteur pharmaceutique, tirant parti de l'expertise de CMS pour diversifier son portefeuille au-delà des applications de nettoyage laser industriel.
Laser Photonics (NASDAQ: LASE) hat zusammen mit seiner kürzlich erworbenen Tochtergesellschaft Control Micro Systems (CMS) die Erweiterung seines Entwicklungsprogramms für Laserbohrtechnik für Tabletten im Pharmamarkt angekündigt. Diese Technologie schafft sub-millimetergroße Löcher in pharmazeutischen Tabletten für osmotische Pumpsysteme zur zeitgesteuerten Medikamentenfreisetzung und verarbeitet bis zu 140.000 Tabletten pro Stunde mit Öffnungen, die so klein wie 200 Mikrometer sind.
Das System verfügt über eine Maschinenvisions-Technologie zur Qualitätskontrolle, die jede Tablette zweimal auf Lochposition, Größe und Anzahl überprüft. Diese Expansion stellt einen strategischen Schritt von LPC in den Pharmasektor dar, indem die Expertise von CMS genutzt wird, um das Portfolio über industrielle Laserreinigungsanwendungen hinaus zu diversifizieren.
- Entry into pharmaceutical market represents significant business expansion opportunity
- High-speed processing capability of 140,000 tablets per hour demonstrates strong operational efficiency
- Advanced quality control system with dual inspection reduces waste and ensures product quality
- None.
Insights
The expansion into pharmaceutical tablet laser drilling represents a significant technological advancement with substantial market potential. The system's capability to process 140,000 tablets per hour with precise 200-micron orifices demonstrates impressive industrial-scale efficiency. The dual quality control system using machine vision technology ensures exceptional accuracy and minimal waste, critical factors for pharmaceutical manufacturing.
The osmotic pump delivery system market is experiencing strong growth due to increasing demand for controlled-release medications. This technology addresses key healthcare challenges by improving medication adherence through reduced dosing frequency and maintaining steady drug levels. The acquisition of Control Micro Systems (CMS) provides LPC with valuable expertise and established technology in this specialized field, positioning them to capture market share in the lucrative pharmaceutical manufacturing sector.
This strategic expansion represents a smart diversification move for LPC, entering the high-value pharmaceutical manufacturing equipment market. The integration of CMS expertise provides immediate technological capabilities and industry credibility. The pharmaceutical manufacturing equipment market offers stable, long-term growth potential due to increasing demand for sophisticated drug delivery systems and automated production solutions.
The focus on precision drilling technology addresses a specific but important niche in pharmaceutical manufacturing, with potential for recurring revenue through maintenance contracts and system upgrades. The company's emphasis on R&D in this sector suggests a long-term commitment to developing advanced solutions, which could lead to expanded market opportunities and increased shareholder value through technological leadership.
Modern Solutions for Manufacturing Time-Release Medication
Tablet laser drilling is a proven, economically viable way to create sub-millimeter apertures in pharmaceutical tablets. This method plays a key role in osmotic pump time-release drug delivery systems, which provide many health benefits like decreasing dosing frequencies, maintaining consistent drug levels in the body over a specific period and enabling customized delivery profiles.
The Tablet Laser Drilling technology by CMS provides an automated, high-speed process capable of drilling up to 140,000 tablets per hour with orifices as small as 200 microns. This technology is engineered to achieve precise dimensional tolerances for osmotic pump tablets and related drug delivery systems, making laser drilling the preferred method for modern pharmaceutical tablet production. Machine vision technology for visual inspection ensures quality and alignment, checking each tablet twice for hole position, size, and/or number before reaching the collection bin. Rejection of produced tablets is rare due to the precision of the system, and any failed tablets are speedily ejected into separate bins.
For LPC, established as a trusted provider of industrial laser equipment, pharmaceutical and medical technologies is a new sector of focus. Supplemented by CMS expertise, LPC is dedicating resources to research and development in this sector in accordance with its broad diversification strategy, poised to contribute to growing shareholder value and foster greater resilience in evolving markets.
“With the expansion of R&D and the integration of CMS expertise, we can rapidly advance our product offerings to meet the high demands of the pharmaceutical industry,” said Wayne Tupuola, CEO of LPC. “Our focus on precision and efficiency is transforming drug delivery systems, ensuring optimal performance and patient safety. We are committed to driving forward the future of pharmaceutical manufacturing with cutting-edge solutions that enhance patient outcomes and streamline production processes.”
For more information, visit the LPC website at www.laserphotonics.com.
About CMS Laser
Control Micro Systems (CMS Laser), is a 40-year
About Laser Photonics Corporation
Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the
Cautionary Note Concerning Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), including statements regarding the Company’s plans, prospects, potential results and use of proceeds. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. These risks include, without limitation, those described under the caption “Risk Factors” in the Registration Statement. Any reader of this press release is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by applicable laws or regulations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205072993/en/
Investor Relations Contact:
laser@haydenir.com
Media Contact:
Karla Kizzort
Marketing Specialist
Laser Photonics Corporation
kkizzort@laserphotonics.com
Source: Laser Photonics Corporation
FAQ
What is Laser Photonics (LASE) tablet laser drilling technology's processing capacity?
How does Laser Photonics (LASE) ensure quality control in tablet drilling?
What market is Laser Photonics (LASE) expanding into with its tablet drilling technology?
